Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib
(cabo) for advanced renal cell carcinoma (RCC) after
anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011
study
LBA417
Adjuvant pembrolizumab plus belzutifan versus
pembrolizumab for clear cell renal cell carcinoma (ccRCC):
The randomized phase 3 LITESPARK-022 study
LBA418
A randomized phase II trial of cytoreductive stereotactic
hypofractionated radiotherapy with ipilimumab/nivolumab for
metastatic kidney cancer.
416
Ascending dose escalation of belzutifan plus palbociclib
for previously treated advanced clear cell renal cell
carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.
423
Cirulating KIM-1 and ctDNA as pronostic markers in
oligometastasic clear cell carcinoma (ccRCC): The
K-KOMPASS model
537
ASCOGU 2026
RENAL
ASCOGU 2026
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Patient-reported outcomes in resected renal cell
carcinoma: Active monitoring vs. durvalumab and
tremelimumab in the RAMPART trial.
420